ALR Technologies (ALRT): Penny Stock, Recent FDA Clearance, Enormous Potential

ALR Technologies Inc. (OTCBB: ALRT), an innovative medical device company, offers a unique software solution aimed at improving patient adherence to care plans  in the diabetes industry working alongside companies like Abbott Laboratories (NYSE: ABT) and Bayer AG (PINK: BAYRY) that develop diabetes testing supplies.

Meanwhile, diabetes is becoming a growing problem around the world. By some estimates, 500 million people, or 1 in 10 adults, will have diabetes by 2030. For more information on these trends and statistics, investors can see the following article:

Undervalued Stock in an Enormous Industry

ALR Technologies has a market capitalization of just $18 million, despite having a late-stage medical device within a multi-billion dollar industry. According to the American Diabetes Association, approximately 25.8 million adults and children have the disease in the U.S., which represents some 8.3% of the population as of 2011 and cost some $174 billion in 2007.

Despite its growing prevalence, many forms of diabetes are preventable. According to the National Institutes of Health, studies have shown that people at high risk for diabetes can prevent or delay onset of the disease by losing 5-7% of their weight. And even if they have diabetes, many of its complications can be avoided by adhering to a diabetes management plan.

The problem is that many people don’t follow their diabetes management plan. Diabetes patients are responsible for more than 95% of their own care and many healthcare professionals express frustration that patients don’t follow diet or exercise plans, check blood sugars or even take their medications as prescribed.

HeC System Makes a World of Difference

ALR Technologies’ Health-e-Connect (HeC) System is an internet-based platform for diabetes patients and their healthcare providers to improve communication and monitoring of a patient’s health management program.  For instance, the software will upload data from a patient’s glucose meter into a database that allows healthcare providers to quickly assess user compliance and test results compared to targets.

In August 2010, Diabetes Care published the results of a trial conducted by Dr. Hugh Tildesley, et al, comparing insulin dependent diabetes patients receiving conventional care with patients that had additional follow-up via an internet based blood glucose monitoring system (IBGMS). The HeC System was the IBGMS deployed in the trial. The study showed A1c dropping from 8.8% to 7.6% over 6 months in the diabetes patients who had the additional IBGMS follow-up. The A1c test is important in diabetes treatment management as a long-term measure of control over blood glucose. In general, every 1% drop in A1c may reduce the risk of microvascular complications by 40%.

In July of 2010, the company submitted a 510(k) application to the FDA for its proprietary HeC System to enable it to market the technology in the U.S. On October 17, 2011, ALR Technologies announced the 510(k) clearance of its HeC system for remote monitoring of patients in support of diabetes management.

A Solid Investment Opportunity

ALR Technologies represents an early stage investment opportunity. With a 510(k) cleared medical device available for the market, the company’s $18 million market capitalization may be significantly undervalued.  Given the efficacy of IBGMS as reported by Dr. Hugh Tildesley, et al, the sales potential of the HeC system could be very large.

For more information on ALR Technologies, please see the following resources: